Latest News

Findings from the phase 3 CheckMate 649 trial support nivolumab plus chemotherapy as a standard frontline therapy for patients with gastric, gastroesophageal junction, and esophageal adenocarcinoma.
Nivolumab/Chemo Yields Meaningful Survival in Advanced Gastric/GEJ Cancer

March 13th 2024

Findings from the phase 3 CheckMate 649 trial support nivolumab plus chemotherapy as a standard frontline therapy for patients with gastric, gastroesophageal junction, and esophageal adenocarcinoma.

Detailing the Impact on SOC in GI Cancer After ASCO GI
Detailing the Impact on SOC in GI Cancer After ASCO GI

March 9th 2024

Over half of the patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma achieve a major pathological complete response following treatment with sintilimab plus FLOT in a phase 2 trial.
Sintilimab Combo Shows Modest Efficacy, Safety in HER2– Gastric/GEJ Cancer

February 18th 2024

Investigators of the AMPLIFY-201 trial hypothesized that ELI-002 2P may induce the expansion of functional tumor-directed KRAS-mutated specific T cells following tumor resection.
Cancer Vaccine Shows Efficacy and Safety Potential in PDAC and CRC

February 13th 2024

Findings from the FRUTIGA study support fruquintinib plus paclitaxel as a promising second-line treatment for those with advanced gastric or gastroesophageal junction adenocarcinoma following prior chemotherapy.
Fruquintinib/Paclitaxel Improves PFS, ORR in Gastric/GEJ Adenocarcinoma

February 7th 2024

More News